Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Primary myelofibrosis, drawn from the whole corpus: 18 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
No drug has been shown to change the course of the disease rather than its symptoms.
Transplant timing: too early risks a fatal procedure in someone with years to live, too late loses the window.
Blast phase myelofibrosis has no effective treatment.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 20 changes by month →When this page itself was last checked or edited.
Myelofibrosis with moderate-to-severe anaemia
Pelabresib plus ruxolitinib roughly doubled the week-24 spleen volume response over ruxolitinib alone; the symptom endpoint did not reach significance.
Intermediate/high-risk myelofibrosis with anaemia
Momelotinib improved symptom response, transfusion independence and spleen response compared with danazol; approved in September 2023.
A milestone in how this cancer is treated.